These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 29684191)

  • 1. Importance of beta-blocker dose in prevention of ventricular tachyarrhythmias, heart failure hospitalizations, and death in primary prevention implantable cardioverter-defibrillator recipients: a Danish nationwide cohort study.
    Ruwald AC; Gislason GH; Vinther M; Johansen JB; Nielsen JC; Philbert BT; Torp-Pedersen C; Riahi S; Jøns C
    Europace; 2018 Sep; 20(FI2):f217-f224. PubMed ID: 29684191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients: insight from Danish nationwide registers.
    Ruwald AC; Gislason GH; Vinther M; Johansen JB; Nielsen JC; Petersen HH; Torp-Pedersen C; Riahi S; Jøns C
    Europace; 2018 Feb; 20(2):301-307. PubMed ID: 28339659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy).
    Ruwald MH; Ruwald AC; Jons C; Alexis J; McNitt S; Zareba W; Moss AJ
    J Am Coll Cardiol; 2013 Apr; 61(14):1518-26. PubMed ID: 23500269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incremental benefit of cardiac resynchronisation therapy with versus without a defibrillator.
    Martens P; Verbrugge FH; Nijst P; Dupont M; Nuyens D; Herendael HV; Rivero-Ayerza M; Tang WH; Mullens W
    Heart; 2017 Dec; 103(24):1977-1984. PubMed ID: 28716973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients.
    Zhou Y; Zhao S; Chen K; Hua W; Su Y; Chen S; Liang Z; Xu W; Zhang S
    BMC Cardiovasc Disord; 2019 Oct; 19(1):230. PubMed ID: 31638918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
    Yazaki K; Suzuki A; Shiga T; Minami Y; Arai K; Ashihara K; Shoda M; Hagiwara N
    BMC Cardiovasc Disord; 2021 Feb; 21(1):106. PubMed ID: 33607967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex Differences in Device Therapies for Ventricular Arrhythmias or Death in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) Trial.
    Tompkins CM; Kutyifa V; Arshad A; McNitt S; Polonsky B; Wang PJ; Moss AJ; Zareba W
    J Cardiovasc Electrophysiol; 2015 Aug; 26(8):862-871. PubMed ID: 25929699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.
    Khazanie P; Hellkamp AS; Fonarow GC; Bhatt DL; Masoudi FA; Anstrom KJ; Heidenreich PA; Yancy CW; Curtis LH; Hernandez AF; Peterson ED; Al-Khatib SM
    J Am Heart Assoc; 2015 Aug; 4(8):e002061. PubMed ID: 26251283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).
    Ruwald MH; Abu-Zeitone A; Jons C; Ruwald AC; McNitt S; Kutyifa V; Zareba W; Moss AJ
    J Am Coll Cardiol; 2013 Oct; 62(15):1343-50. PubMed ID: 23770172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of device detected atrial and ventricular tachyarrhythmia with adverse events in patients with an implantable cardioverter-defibrillator.
    Abbas H; Younis A; Goldenberg I; McNitt S; Aktas MK; Tabaja C; Ojo A
    J Cardiovasc Electrophysiol; 2024 Jun; 35(6):1203-1211. PubMed ID: 38606650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic implantable cardioverter defibrillators for primary prevention: From implantation to heart transplantation.
    Algalarrondo V; Perault R; Bories MC; Narayanan K; Garcia R; Combes N; Perier MC; Defaye P; Sadoul N; Gras D; Klug D; Bordachar P; Fauchier L; Deharo JC; Leclercq C; Boveda S; Marijon E; Babuty D;
    Arch Cardiovasc Dis; 2018 Dec; 111(12):758-765. PubMed ID: 30078651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
    Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
    Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication.
    Schaer B; Kühne M; Reichlin T; Osswald S; Sticherling C
    Europace; 2016 Feb; 18(2):227-31. PubMed ID: 26063686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ventricular tachyarrhythmia characteristics in patients with idiopathic dilated or ischemic cardiomyopathy and defibrillators implanted for primary prevention.
    Streitner F; Kuschyk J; Dietrich C; Mahl E; Streitner I; Doesch C; Veltmann C; Schimpf R; Wolpert C; Borggrefe M
    Clin Cardiol; 2011 Oct; 34(10):604-9. PubMed ID: 21887690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of anti-arrhythmic efficacy of carvedilol vs metoprolol succinate in patients with implantable cardioverter-defibrillators.
    Ayan M; Habash F; Alqam B; Gheith Z; Cross M; Vallurupalli S; Paydak H
    Clin Cardiol; 2019 Feb; 42(2):299-304. PubMed ID: 30592068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrial fibrillation increases the risk of recurrent ventricular tachyarrhythmias in implantable cardioverter defibrillator recipients.
    Rusnak J; Behnes M; Reiser L; Schupp T; Bollow A; Reichelt T; Borggrefe M; Ellguth D; Engelke N; El-Battrawy I; Ansari U; Barre M; Weidner K; Müller J; Barth C; Meininghaus DG; Akin M; Bertsch T; Taton G; Akin I
    Arch Cardiovasc Dis; 2021; 114(6-7):443-454. PubMed ID: 33967015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implantable cardioverter defibrillator therapy in paediatric patients for primary vs. secondary prevention.
    Thuraiaiyah J; Philbert BT; Jensen AS; Xing LY; Joergensen TH; Lim CW; Jakobsen FN; Bække PS; Schmidt MR; Idorn L; Holdgaard Smerup M; Johansen JB; Riahi S; Nielsen JC; De Backer O; Sondergaard L; Jons C
    Europace; 2024 Aug; 26(9):. PubMed ID: 39345160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome in patients with implantable cardioverter-defibrillator and cancer: a nationwide study.
    Christensen AM; Bjerre J; Schou M; Jons C; Vinther M; Gislason GH; Johansen JB; Nielsen JC; Petersen HH; Riahi S; Ruwald AC
    Europace; 2019 Mar; 21(3):465-474. PubMed ID: 30535192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional Longitudinal Deformation Improves Prediction of Ventricular Tachyarrhythmias in Patients With Heart Failure With Reduced Ejection Fraction: A MADIT-CRT Substudy (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy).
    Biering-Sørensen T; Knappe D; Pouleur AC; Claggett B; Wang PJ; Moss AJ; Solomon SD; Kutyifa V
    Circ Cardiovasc Imaging; 2017 Jan; 10(1):. PubMed ID: 28003221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Carvedilol vs Metoprolol on Atrial and Ventricular Arrhythmias Among Implantable Cardioverter-Defibrillator Recipients.
    Diamond A; Goldenberg I; Younis A; Goldenberg I; Sampath R; Kutyifa V; Chen AY; McNitt S; Polonsky B; Steinberg JS; Zareba W; Aktaş MK
    JACC Clin Electrophysiol; 2023 Oct; 9(10):2122-2131. PubMed ID: 37656097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.